Epigenome Technologies Multiplex Droplet Paired-Tag - 8 Reaction Kit
SKU MDP8101
In stock
1
Save this product for later
Epigenome Technologies Multiplex Droplet Paired-Tag - 8 Reaction Kit
Product Details
Epigenome Technologie Multiplex Droplet Paired-Tag builds on our standard Droplet Paired-Tag technology by using uniquely barcoded oligos during tagmentation. This innovation lets you combine multiple assays within a single 10x Chromium® lane—dramatically boosting throughput without sacrificing data quality. By pooling up to four assays in one run, researchers can capture as many as 30,000 nuclei total (approximately 7,500 per assay), making it an ideal choice for labs that need to profile multiple conditions, marks, or time points efficiently.
Key Advantages
- ✅ Multi-Condition Profiling: Run up to four assays in parallel
- ✅ Cost Savings: Reduce per-assay sequencing and reagent costs
- ✅ Preserved Data Quality: Barcoded oligos ensure accuracy
- ✅ Flexible Applications: Ideal for disease research, drug screening, and time-course studies
Application
Experience precision medicine at its finest with the Multiplex Droplet Paired-Tag - 8 Reaction Kit. Save on reagent and sequencing costs by multiplexing experiments, enabling multiple Droplet Paired-Tag experiments to be overloaded into the same 10X lane. This kit supports up to 4X overload (64,000 nuclei) and profiles simultaneous single-cell RNA and Cut&Tag libraries at ultra-high throughput. A 10X multiome kit is required to operate this groundbreaking tool. Advance your research and unlock single-cell resolution with Epigenome Technology's precise and efficient solutions.
Performance
- 📊 Throughput & Coverage: Multiplex Paired-Tag captures thousands of cells per run with high UMI counts. Tissue data from human brain and PBMC show robust DNA and RNA readouts, with broad histone marks reaching 5000+ UMIs per cell.
- 🧪 Versatility: Compatible with fresh, frozen, and cryopreserved samples, supporting histone PTMs, chromatin remodelers, and transcription factors.
- 🎯Robustness: Strong correlation between bulk and single-cell profiling ensures high reproducibility and confidence in results.
What You Need to Get Started
- Antibody: Validated primary antibody for target of interest
- Single-Cell Platform: 10x Genomics Chromium
- Reagents: 10x Genomics Multiome Kit
- Sequencing: Illumina-compatible sequencing system
Company Profile
Epigenome Technologies emerged in 2022 as a spin-out from the pioneering Bing Ren lab at UC San Diego. Recognizing the transformative power of single-cell epigenetic profiling, our founders—Professor Bing Ren (UCSD epigenetics expert and former Harvard postdoc) and Pei Lin (with leadership experience at Illumina and the Salk Institute)—joined forces to brin g cutting-edge single-cell and spatial DNA-binding solutions to the broader research community.
Milestones & Achievements
- $6M in SBIR Grants: Sustaining robust R&D to enhance and expand our epigenetic toolkits.
- BRAIN Initiative: Our flagship technology, Paired-Tag, is actively utilized as part of this prestigious research program.
- High-Profile Publications: Our techniques feature in leading journals, including Nature Methods and Nature Communications, showcasing breakthroughs in single-cell epigenomics and metabolic stress response.
Technology & Differentiation
- First-Mover Advantage: We are among the very first to offer single-cell epigenetic profiling at scale, coupled with a unique multi-omic spatial solution.
- Broad Platform Compatibility: Seamless integration with numerous single-cell systems grants researchers the flexibility to choose a workflow that aligns with their lab infrastructure.
- Impact on Research & Medicine: By mapping regulatory mechanisms that underlie aberrant gene expression, we open new avenues for identifying therapeutic targets and delivering actionable clinical insights.
Our comprehensive approach to gene regulation sets us apart in a competitive biotech landscape. We’ve already proven that single-cell and spatial epigenetic profiling can unlock novel diagnostic markers and inform targeted therapies for conditions previously deemed intractable. As we continue to scale, we welcome conversations with potential acquirers and strategic partners who share our vision for revolutionizing the future of genomic research.
Display prices in:EUR
